Ozarelix Stocks List
- Ozarelix
Ozarelix (developmental code names D-63153, SPI-153) is a peptide gonadotropin-releasing hormone antagonist (GnRH antagonist) which is or was under development by AEterna Zentaris Inc. and Spectrum Pharmaceuticals as a long-acting injection formulation for the treatment of prostate cancer. It has also been investigated for the treatment of endometriosis, but no development has been reported. The drug was previously under investigation for the treatment of benign prostatic hyperplasia and Alzheimer's disease as well, but development for these indications was discontinued. As of June 2015, it was in phase II clinical trials for prostate cancer. It seems to no longer be under development.
Popular Now
Recent Comments
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
- TraderMike on Trades of the Week: Feb 12 - Feb 16, 2024
- Cos3 on Trades of the Week: Feb 12 - Feb 16, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
From the Blog
Featured Articles